Monday, February 6 2012 4:05 PM EST2012-02-06 21:05:06 GMT
Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Pomerantz LLP
NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oramed Pharmaceuticals, Inc. ("Oramed" or the "Company") (NasdaqGS: ORMP). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Oramed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On Monday February 3, 2014, a report was published on TheStreet.com website questioning the integrity and robustness of the data presented by the Company regarding its Oral Insulin Pill, with the report calling such data "Completely Worthless".
On this news, shares of Oramed fell $3.85 per share to $18.24, or more than 17.43%, on February 3, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.